# Clinical Study of ET190L1 ARTEMIS™ in Relapsed, Refractory B Cell Lymphoma

> **NCT03415399** · PHASE1 · COMPLETED · sponsor: **Eureka Therapeutics Inc.** · enrollment: 4 (actual)

## Conditions studied

- Lymphoma, B-Cell

## Interventions

- **BIOLOGICAL:** ET190L1 ARTEMIS™ T cells

## Key facts

- **NCT ID:** NCT03415399
- **Lead sponsor:** Eureka Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-09
- **Primary completion:** 2020-12-31
- **Final completion:** 2020-12-31
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2021-03-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03415399

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03415399, "Clinical Study of ET190L1 ARTEMIS™ in Relapsed, Refractory B Cell Lymphoma". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03415399. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*